Quantbot Technologies LP Acquires New Holdings in Omada Health, Inc. $OMDA

Posted by Stanley Muller on Aug 25th, 2026

Quantbot Technologies LP bought a new position in Omada Health, Inc. (NASDAQ:OMDA – Free Report) in the 2nd quarter, HoldingsChannel reports. The institutional investor bought 77,200 shares of the company’s stock, valued at approximately $1,695,000.

A number of other large investors have also recently added to or reduced their stakes in OMDA. Quarry LP bought a new position in shares of Omada Health in the fourth quarter valued at approximately $29,000. TD Waterhouse Canada Inc. bought a new stake in shares of Omada Health during the 4th quarter worth $32,000. Raymond James Financial Inc. bought a new stake in shares of Omada Health during the 2nd quarter worth $32,000. Versant Capital Management Inc grew its stake in Omada Health by 319.3% in the 2nd quarter. Versant Capital Management Inc now owns 2,998 shares of the company’s stock valued at $66,000 after buying an additional 2,283 shares during the last quarter. Finally, Strs Ohio grew its stake in Omada Health by 151.0% in the 4th quarter. Strs Ohio now owns 4,267 shares of the company’s stock valued at $67,000 after buying an additional 2,567 shares during the last quarter.

Omada Health Trading Up 0.8%

Shares of OMDA stock opened at $24.08 on Tuesday. The firm has a market capitalization of $1.47 billion, a P/E ratio of 481.60 and a beta of 1.73. Omada Health, Inc. has a 1 year low of $10.28 and a 1 year high of $26.92. The firm’s fifty day simple moving average is $21.75 and its 200 day simple moving average is $16.87.

Omada Health (NASDAQ:OMDA – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.10. The firm had revenue of $87.83 million during the quarter, compared to the consensus estimate of $80.93 million. Omada Health had a net margin of 1.39% and a return on equity of 2.60%. Equities research analysts anticipate that Omada Health, Inc. will post 0.09 EPS for the current fiscal year.

Insider Transactions at Omada Health

In related news, CEO Sean P. Duffy sold 25,886 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $22.68, for a total value of $587,094.48. Following the completion of the sale, the chief executive officer owned 411,861 shares in the company, valued at approximately $9,341,007.48. This trade represents a 5.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Steven L. Cook sold 33,000 shares of the business’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $19.89, for a total value of $656,370.00. Following the transaction, the chief financial officer owned 133,359 shares in the company, valued at $2,652,510.51. This represents a 19.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 254,726 shares of company stock valued at $5,370,496 in the last ninety days. 6.38% of the stock is owned by company insiders.

Analysts Set New Price Targets

OMDA has been the subject of a number of research analyst reports. Robert W. Baird boosted their target price on shares of Omada Health from $15.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price target on shares of Omada Health in a research report on Friday, May 8th. Weiss Ratings upgraded Omada Health from a “sell (e+)” rating to a “sell (d+)” rating in a research note on Tuesday, August 11th. Evercore reissued an “outperform” rating and set a $20.00 price objective on shares of Omada Health in a research report on Friday, May 8th. Finally, Barclays increased their target price on Omada Health from $20.00 to $25.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $26.50.

Check Out Our Latest Report on Omada Health

Omada Health Profile

(Free Report)

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.